vs
艾伯维（ABBV）与Surgery Partners, Inc.（SGRY）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是Surgery Partners, Inc.的18.8倍（$16.6B vs $885.0M）。艾伯维净利率更高（10.9% vs -1.7%，领先12.6%）。艾伯维同比增速更快（10.0% vs 2.4%）。艾伯维自由现金流更多（$4.9B vs $90.6M）。过去两年艾伯维的营收复合增速更高（16.2% vs 11.1%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
Surgery Partners, Inc.（NASDAQ代码：SGRY）旗下的United Surgical Partners International（USPI）是美国领先的日间手术护理服务商，总部位于得克萨斯州达拉斯，由唐·斯廷于1998年创立，专注于为患者提供便捷、高效的门诊外科医疗服务，运营多家合规手术中心，覆盖美国多地医疗需求场景。
ABBV vs SGRY — 直观对比
营收规模更大
ABBV
是对方的18.8倍
$885.0M
营收增速更快
ABBV
高出7.7%
2.4%
净利率更高
ABBV
高出12.6%
-1.7%
自由现金流更多
ABBV
多$4.8B
$90.6M
两年增速更快
ABBV
近两年复合增速
11.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $885.0M |
| 净利润 | $1.8B | $-15.0M |
| 毛利率 | 72.6% | — |
| 营业利润率 | 27.3% | 12.5% |
| 净利率 | 10.9% | -1.7% |
| 营收同比 | 10.0% | 2.4% |
| 净利润同比 | 8354.5% | 86.2% |
| 每股收益（稀释后） | $1.02 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVSGRY
| Q4 25 | $16.6B | $885.0M | ||
| Q3 25 | $15.8B | $821.5M | ||
| Q2 25 | $15.4B | $826.2M | ||
| Q1 25 | $13.3B | $776.0M | ||
| Q4 24 | $15.1B | $864.4M | ||
| Q3 24 | $14.5B | $770.4M | ||
| Q2 24 | $14.5B | $762.1M | ||
| Q1 24 | $12.3B | $717.4M |
净利润ABBVSGRY
| Q4 25 | $1.8B | $-15.0M | ||
| Q3 25 | $186.0M | $-22.7M | ||
| Q2 25 | $938.0M | $-2.5M | ||
| Q1 25 | $1.3B | $-37.7M | ||
| Q4 24 | $-22.0M | $-108.5M | ||
| Q3 24 | $1.6B | $-31.7M | ||
| Q2 24 | $1.4B | $-15.5M | ||
| Q1 24 | $1.4B | $-12.4M |
毛利率ABBVSGRY
| Q4 25 | 72.6% | — | ||
| Q3 25 | 66.4% | — | ||
| Q2 25 | 71.8% | — | ||
| Q1 25 | 70.0% | — | ||
| Q4 24 | 70.9% | — | ||
| Q3 24 | 70.9% | — | ||
| Q2 24 | 70.9% | — | ||
| Q1 24 | 66.7% | — |
营业利润率ABBVSGRY
| Q4 25 | 27.3% | 12.5% | ||
| Q3 25 | 12.1% | 12.9% | ||
| Q2 25 | 31.7% | 13.5% | ||
| Q1 25 | 28.0% | 8.0% | ||
| Q4 24 | -9.9% | 14.7% | ||
| Q3 24 | 26.5% | 7.9% | ||
| Q2 24 | 27.6% | 11.1% | ||
| Q1 24 | 22.7% | 10.6% |
净利率ABBVSGRY
| Q4 25 | 10.9% | -1.7% | ||
| Q3 25 | 1.2% | -2.8% | ||
| Q2 25 | 6.1% | -0.3% | ||
| Q1 25 | 9.6% | -4.9% | ||
| Q4 24 | -0.1% | -12.6% | ||
| Q3 24 | 10.8% | -4.1% | ||
| Q2 24 | 9.5% | -2.0% | ||
| Q1 24 | 11.1% | -1.7% |
每股收益（稀释后）ABBVSGRY
| Q4 25 | $1.02 | $-0.11 | ||
| Q3 25 | $0.10 | $-0.18 | ||
| Q2 25 | $0.52 | $-0.02 | ||
| Q1 25 | $0.72 | $-0.30 | ||
| Q4 24 | $-0.03 | $-0.86 | ||
| Q3 24 | $0.88 | $-0.25 | ||
| Q2 24 | $0.77 | $-0.12 | ||
| Q1 24 | $0.77 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $239.9M |
| 总债务越低越好 | $58.9B | $3.6B |
| 股东权益账面价值 | $-3.3B | $1.7B |
| 总资产 | $134.0B | $8.1B |
| 负债/权益比越低杠杆越低 | — | 2.10× |
8季度趋势，按日历期对齐
现金及短期投资ABBVSGRY
| Q4 25 | $5.3B | $239.9M | ||
| Q3 25 | $5.7B | $203.4M | ||
| Q2 25 | $6.5B | $250.1M | ||
| Q1 25 | $5.2B | $229.3M | ||
| Q4 24 | $5.6B | $269.5M | ||
| Q3 24 | $7.3B | $221.8M | ||
| Q2 24 | $13.2B | $213.5M | ||
| Q1 24 | $18.1B | $185.2M |
总债务ABBVSGRY
| Q4 25 | $58.9B | $3.6B | ||
| Q3 25 | $63.0B | $3.5B | ||
| Q2 25 | $63.0B | $3.5B | ||
| Q1 25 | $64.5B | $3.4B | ||
| Q4 24 | $60.3B | $3.3B | ||
| Q3 24 | $58.5B | $3.1B | ||
| Q2 24 | $58.0B | $3.0B | ||
| Q1 24 | $63.8B | $2.8B |
股东权益ABBVSGRY
| Q4 25 | $-3.3B | $1.7B | ||
| Q3 25 | $-2.6B | $1.7B | ||
| Q2 25 | $-183.0M | $1.7B | ||
| Q1 25 | $1.4B | $1.7B | ||
| Q4 24 | $3.3B | $1.8B | ||
| Q3 24 | $6.0B | $1.9B | ||
| Q2 24 | $6.8B | $2.0B | ||
| Q1 24 | $8.0B | $2.0B |
总资产ABBVSGRY
| Q4 25 | $134.0B | $8.1B | ||
| Q3 25 | $133.9B | $7.9B | ||
| Q2 25 | $137.2B | $8.0B | ||
| Q1 25 | $136.2B | $7.9B | ||
| Q4 24 | $135.2B | $7.9B | ||
| Q3 24 | $143.4B | $7.5B | ||
| Q2 24 | $141.9B | $7.5B | ||
| Q1 24 | $148.9B | $7.0B |
负债/权益比ABBVSGRY
| Q4 25 | — | 2.10× | ||
| Q3 25 | — | 2.00× | ||
| Q2 25 | — | 1.98× | ||
| Q1 25 | 45.44× | 1.98× | ||
| Q4 24 | 18.15× | 1.83× | ||
| Q3 24 | 9.70× | 1.63× | ||
| Q2 24 | 8.56× | 1.56× | ||
| Q1 24 | 7.97× | 1.42× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $103.4M |
| 自由现金流经营现金流 - 资本支出 | $4.9B | $90.6M |
| 自由现金流率自由现金流/营收 | 29.4% | 10.2% |
| 资本支出强度资本支出/营收 | 2.0% | 1.4% |
| 现金转化率经营现金流/净利润 | 2.87× | — |
| 过去12个月自由现金流最近4个季度 | $17.8B | $195.6M |
8季度趋势，按日历期对齐
经营现金流ABBVSGRY
| Q4 25 | $5.2B | $103.4M | ||
| Q3 25 | $7.0B | $83.6M | ||
| Q2 25 | $5.2B | $81.3M | ||
| Q1 25 | $1.6B | $6.0M | ||
| Q4 24 | $7.0B | $111.4M | ||
| Q3 24 | $5.4B | $65.2M | ||
| Q2 24 | $2.3B | $82.8M | ||
| Q1 24 | $4.0B | $40.7M |
自由现金流ABBVSGRY
| Q4 25 | $4.9B | $90.6M | ||
| Q3 25 | $6.6B | $63.8M | ||
| Q2 25 | $4.9B | $57.9M | ||
| Q1 25 | $1.4B | $-16.7M | ||
| Q4 24 | $6.8B | $89.1M | ||
| Q3 24 | $5.2B | $45.0M | ||
| Q2 24 | $2.0B | $55.9M | ||
| Q1 24 | $3.8B | $19.7M |
自由现金流率ABBVSGRY
| Q4 25 | 29.4% | 10.2% | ||
| Q3 25 | 42.1% | 7.8% | ||
| Q2 25 | 31.7% | 7.0% | ||
| Q1 25 | 10.5% | -2.2% | ||
| Q4 24 | 44.7% | 10.3% | ||
| Q3 24 | 35.9% | 5.8% | ||
| Q2 24 | 14.0% | 7.3% | ||
| Q1 24 | 31.3% | 2.7% |
资本支出强度ABBVSGRY
| Q4 25 | 2.0% | 1.4% | ||
| Q3 25 | 2.4% | 2.4% | ||
| Q2 25 | 1.7% | 2.8% | ||
| Q1 25 | 1.8% | 2.9% | ||
| Q4 24 | 1.9% | 2.6% | ||
| Q3 24 | 1.7% | 2.6% | ||
| Q2 24 | 1.7% | 3.5% | ||
| Q1 24 | 1.6% | 2.9% |
现金转化率ABBVSGRY
| Q4 25 | 2.87× | — | ||
| Q3 25 | 37.76× | — | ||
| Q2 25 | 5.49× | — | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.49× | — | ||
| Q2 24 | 1.66× | — | ||
| Q1 24 | 2.95× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABBV
暂无分部数据
SGRY
| Private Insurance | $460.5M | 52% |
| Government Revenue | $368.6M | 42% |
| Other | $19.8M | 2% |
| Self Pay Revenue | $19.6M | 2% |
| Other Patient Service Revenue Sources | $16.5M | 2% |
